REPORTS

Let’s Pullulate and Expand Your Business

Diabetes Drug Market - Global Professional Analysis and Forecast to 2026

Nov 16, 2019  |  159 PAGES  |  REPORT CODE: CMM238303
  • REPORT SUMMARY
  • TABLE OF CONTENTS
  • INDUSTRY COVERAGE

The worldwide Diabetes Drug market was valued at XX.0 Million US$ in 2018 and is projected to reach XX.0 Million US$ by 2026, at a CAGR (Compound Annual Growth Rate) of 6.5% during the forecast period.

This report presents the market size and development trends by detailing the Diabetes Drug market revenue, market share and growth rate from 2015-2026, and it gives a thorough analysis by various product types, applications, regions, and main participants. The market conditions (2015-2019), corporate competition pattern, corporate SWOT analysis are elaborated, and other qualitative analyses like market dynamics, market penetration, market business environment analyses, the regional regulatory scenario in the Diabetes Drug market will be shown in this report. In short, this report will comprehensively reveal the characteristics of Diabetes Drug industry and will help you to build a panoramic view of the industrial development.

Diabetes Drug Market, By Type:

  • Sulphonylureas

  • Biguanides

  • Meglitinides

  • Thiazolidinediones

  • Alpha-glucosidase Inhibitors

  • DPP-4 Inhibitors

  • SGLT-2 Inhibitors

Diabetes Drug Market, By Application:

  • Type 1 Diabetes

  • Type 2 Diabetes

  • Gestational Diabetes

  • Impaired Glucose Tolerance and Impaired Fasting Glycaemia

Some of the leading players are as follows:

  • Julphar.

  • Novartis, Astellas

  • Boehringer Ingelheim.

  • Sanofi.

  • Bristol Myers Squibb.

  • Eli Lilly.

  • Biocon.

  • Pfizer.

  • Exir.

  • AstraZeneca.

  • Wockhardt.

  • Abbott Laboratories.

  • Merck.

  • Mylan.

  • NovoNordisk.

  • SEDICO.

  • Johnson & Johnson.

  • GlaxoSmithKline PLC.

Geographically, Major regions are analyzed in details are as follows:

  • North America

  • Europe

  • Asia Pacific

  • Latin America

  • Middle East & Africa

Table of Contents

1 Methodology and Scope

  • 1.1 Market Segmentation & Scope

    • 1.1.1 Technology Type

    • 1.1.2 Product

    • 1.1.3 Application

    • 1.1.4 Regional scope

    • 1.1.5 Estimates and forecast timeline

  • 1.2 Research Methodology

  • 1.3 Information Procurement

    • 1.3.1 Purchased database

    • 1.3.2 Internal database

    • 1.3.3 Secondary sources

    • 1.3.4 Primary research

    • 1.3.5 Details of primary research

  • 1.4 Information or Data Analysis

    • 1.4.1 Data analysis models

  • 1.5 Market Formulation & Validation

  • 1.6 Model Details

    • 1.6.1 Commodity flow analysis

    • 1.6.2 Volume price analysis

  • 1.7 List of Secondary Sources

  • 1.8 List of Abbreviations

2 Executive Summary

  • 2.1 Market Outlook

  • 2.2 Segment Outlook

3 Market Variables, Trends, & Scope

  • 3.1 Market Lineage Outlook

  • 3.1.1 Parent market outlook

    • 3.1.2 Ancillary market outlook

  • 3.2 Market Segmentation

    • 3.2.1 Analysis

  • 3.3 Market Dynamics

    • 3.3.1 Market driver analysis

    • 3.3.2 Market restraint analysis

    • 3.3.3 Industry opportunities

  • 3.4 Penetration & Growth Prospect Mapping

    • 3.4.1 Penetration & growth prospect mapping analysis

  • 3.5 Business Environment Analysis Tools

    • 3.5.1 Porter's five forces analysis

    • 3.5.2 PESTLE analysis

    • 3.5.3 Major deals & strategic alliances analysis

4 Diabetes Drug Market: Technology Type Analysis

  • 4.1 Diabetes Drug Technology Type Market Share Analysis, 2018 & 2026

  • 4.2 Diabetes Drug Technology Type Market: Segment Dashboard

  • 4.3 Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the Technology Type Segment

    • 4.3.1 Sulphonylureas

    • 4.3.2 Biguanides

    • 4.3.3 Meglitinides

    • 4.3.4 Thiazolidinediones

    • 4.3.5 Alpha-glucosidase Inhibitors

    • 4.3.6 DPP-4 Inhibitors

    • 4.3.7 SGLT-2 Inhibitors

5 Diabetes Drug Market: Product Analysis

  • 5.1 Diabetes Drug Product Market Share Analysis, 2018 & 2026

  • 5.2 Diabetes Drug Product Market: Segment Dashboard

  • 5.3 Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the Product Segment

6 Diabetes Drug Market: Application Analysis

  • 6.1 Diabetes Drug Application Market Share Analysis, 2018 & 2026

  • 6.2 Diabetes Drug Application Market: Segment Dashboard

  • 6.3 Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the Application Segment

    • 6.3.1 Type 1 Diabetes

    • 6.3.2 Type 2 Diabetes

    • 6.3.3 Gestational Diabetes

    • 6.3.4 Impaired Glucose Tolerance and Impaired Fasting Glycaemia

7 Diabetes Drug Market: Regional Analysis

  • 7.1 Diabetes Drug Regional Market Share Analysis, 2018 & 2026

  • 7.2 Diabetes Drug Regional Market: Segment Dashboard

  • 7.3 Regional Market Snapshot (Market Size, CAGR, Top Countries)

  • 7.4 List of Players at Regional Level

    • 7.4.1 North America

    • 7.4.2 Europe

    • 7.4.3 Asia Pacific

  • 7.5 SWOT Analysis, by Factor (Political & Legal, Economic and Technological)

    • 7.5.1 North America

    • 7.5.2 Europe

    • 7.5.3 Asia Pacific

    • 7.5.4 Latin America

    • 7.5.5 MEA

  • 7.6 Market Size & Forecasts, and Trend Analysis, 2015 to 2026

    • 7.6.1 North America

    • 7.6.2 Europe

    • 7.6.3 Asia Pacific

    • 7.6.4 Latin America

    • 7.6.5 Middle East & Africa

8 Competitive Analysis

  • 8.1 Recent Developments & Impact Analysis, by Key Market Participants

  • 8.2 Strategic Framework/Competition Categorization (Key innovators, Market leaders, Emerging players)

  • 8.3 Vendor Landscape

    • 8.3.1 Company market position analysis (Geographic presence, service portfolio, strategic initiatives)

9 Company Profiles

  • 9.1 Julphar.

    • 9.1.1 Julphar. Company overview

    • 9.1.2 Financial performance

    • 9.1.3 Product benchmarking

    • 9.1.4 Strategic initiatives

    • 9.1.5 SWOT analysis

  • 9.2 Novartis, Astellas

    • 9.2.1 Novartis, Astellas Company overview

    • 9.2.2 Financial performance

    • 9.2.3 Product benchmarking

    • 9.2.4 Strategic initiatives

    • 9.2.5 SWOT analysis

  • 9.3 Boehringer Ingelheim.

    • 9.3.1 Boehringer Ingelheim. Company overview

    • 9.3.2 Financial performance

    • 9.3.3 Product benchmarking

    • 9.3.4 Strategic initiatives

    • 9.3.5 SWOT analysis

  • 9.4 Sanofi.

    • 9.4.1 Sanofi. Company overview

    • 9.4.2 Financial performance

    • 9.4.3 Product benchmarking

    • 9.4.4 Strategic initiatives

    • 9.4.5 SWOT analysis

  • 9.5 Bristol Myers Squibb.

    • 9.5.1 Bristol Myers Squibb. Company overview

    • 9.5.2 Financial performance

    • 9.5.3 Product benchmarking

    • 9.5.4 Strategic initiatives

    • 9.5.5 SWOT analysis

  • 9.6 Eli Lilly.

    • 9.6.1 Eli Lilly. Company overview

    • 9.6.2 Financial performance

    • 9.6.3 Product benchmarking

    • 9.6.4 Strategic initiatives

    • 9.6.5 SWOT analysis

  • 9.7 Biocon.

    • 9.7.1 Biocon. Company overview

    • 9.7.2 Financial performance

    • 9.7.3 Product benchmarking

    • 9.7.4 Strategic initiatives

    • 9.7.5 SWOT analysis

  • 9.8 Pfizer.

    • 9.8.1 Pfizer. Company overview

    • 9.8.2 Financial performance

    • 9.8.3 Product benchmarking

    • 9.8.4 Strategic initiatives

    • 9.8.5 SWOT analysis

  • 9.9 Exir.

    • 9.9.1 Exir. Company overview

    • 9.9.2 Financial performance

    • 9.9.3 Product benchmarking

    • 9.9.4 Strategic initiatives

    • 9.9.5 SWOT analysis

  • 9.10 AstraZeneca.

    • 9.10.1 AstraZeneca. Company overview

    • 9.10.2 Financial performance

    • 9.10.3 Product benchmarking

    • 9.10.4 Strategic initiatives

    • 9.10.5 SWOT analysis

  • 9.11 Wockhardt.

    • 9.11.1 Wockhardt. Company overview

    • 9.11.2 Financial performance

    • 9.11.3 Product benchmarking

    • 9.11.4 Strategic initiatives

    • 9.11.5 SWOT analysis

  • 9.12 Abbott Laboratories.

    • 9.12.1 Abbott Laboratories. Company overview

    • 9.12.2 Financial performance

    • 9.12.3 Product benchmarking

    • 9.12.4 Strategic initiatives

    • 9.12.5 SWOT analysis

  • 9.13 Merck.

    • 9.13.1 Merck. Company overview

    • 9.13.2 Financial performance

    • 9.13.3 Product benchmarking

    • 9.13.4 Strategic initiatives

    • 9.13.5 SWOT analysis

  • 9.14 Mylan.

    • 9.14.1 Mylan. Company overview

    • 9.14.2 Financial performance

    • 9.14.3 Product benchmarking

    • 9.14.4 Strategic initiatives

    • 9.14.5 SWOT analysis

  • 9.15 NovoNordisk.

    • 9.15.1 NovoNordisk. Company overview

    • 9.15.2 Financial performance

    • 9.15.3 Product benchmarking

    • 9.15.4 Strategic initiatives

    • 9.15.5 SWOT analysis

  • 9.16 SEDICO.

    • 9.16.1 SEDICO. Company overview

    • 9.16.2 Financial performance

    • 9.16.3 Product benchmarking

    • 9.16.4 Strategic initiatives

    • 9.16.5 SWOT analysis

  • 9.17 Johnson & Johnson.

    • 9.17.1 Johnson & Johnson. Company overview

    • 9.17.2 Financial performance

    • 9.17.3 Product benchmarking

    • 9.17.4 Strategic initiatives

    • 9.17.5 SWOT analysis

  • 9.18 GlaxoSmithKline PLC.

    • 9.18.1 GlaxoSmithKline PLC. Company overview

    • 9.18.2 Financial performance

    • 9.18.3 Product benchmarking

    • 9.18.4 Strategic initiatives

    • 9.18.5 SWOT analysis

 

The List of Tables and Figures (Totals 65 Figures and 137 Tables)

  • Figure Sulphonylureas Diabetes Drug market, 2015 - 2026 (USD Million)

  • Figure Biguanides Diabetes Drug market, 2015 - 2026 (USD Million)

  • Figure Meglitinides Diabetes Drug market, 2015 - 2026 (USD Million)

  • Figure Thiazolidinediones Diabetes Drug market, 2015 - 2026 (USD Million)

  • Figure Alpha-glucosidase Inhibitors Diabetes Drug market, 2015 - 2026 (USD Million)

  • Figure DPP-4 Inhibitors Diabetes Drug market, 2015 - 2026 (USD Million)

  • Figure SGLT-2 Inhibitors Diabetes Drug market, 2015 - 2026 (USD Million)

  • Figure Type 1 Diabetes market, 2015 - 2026 (USD Million)

  • Figure Type 2 Diabetes market, 2015 - 2026 (USD Million)

  • Figure Gestational Diabetes market, 2015 - 2026 (USD Million)

  • Figure Impaired Glucose Tolerance and Impaired Fasting Glycaemia market, 2015 - 2026 (USD Million)

  • Table List of players in North America

  • Table List of players in Europe

  • Table List of players in Asia Pacific

  • Table SWOT analysis

  • Table North America Diabetes Drug market, by country, 2015 - 2026 (USD Million)

  • Table North America Diabetes Drug market, by type, 2015 - 2026 (USD Million)

  • Table North America Diabetes Drug market, by product, 2015 - 2026 (USD Million)

  • Table North America Diabetes Drug market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table U.S. Diabetes Drug market, by type, 2015 - 2026 (USD Million)

  • Table U.S. Diabetes Drug market, by product, 2015 - 2026 (USD Million)

  • Table U.S. Diabetes Drug market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Canada Diabetes Drug market, by type, 2015 - 2026 (USD Million)

  • Table Canada Diabetes Drug market, by product, 2015 - 2026 (USD Million)

  • Table Canada Diabetes Drug market, by application, 2015 - 2026 (USD Million)

  • Table Europe Diabetes Drug market, by country, 2015 - 2026 (USD Million)

  • Table Europe Diabetes Drug market, by type, 2015 - 2026 (USD Million)

  • Table Europe Diabetes Drug market, by product, 2015 - 2026 (USD Million)

  • Table Europe Diabetes Drug market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table U.K. Diabetes Drug market, by type, 2015 - 2026 (USD Million)

  • Table U.K. Diabetes Drug market, by product, 2015 - 2026 (USD Million)

  • Table U.K. Diabetes Drug market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Germany Diabetes Drug market, by type, 2015 - 2026 (USD Million)

  • Table Germany Diabetes Drug market, by product, 2015 - 2026 (USD Million)

  • Table Germany Diabetes Drug market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table France Diabetes Drug market, by type, 2015 - 2026 (USD Million)

  • Table France Diabetes Drug market, by product, 2015 - 2026 (USD Million)

  • Table France Diabetes Drug market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Italy Diabetes Drug market, by type, 2015 - 2026 (USD Million)

  • Table Italy Diabetes Drug market, by product, 2015 - 2026 (USD Million)

  • Table Italy Diabetes Drug market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Spain Diabetes Drug market, by type, 2015 - 2026 (USD Million)

  • Table Spain Diabetes Drug market, by product, 2015 - 2026 (USD Million)

  • Table Spain Diabetes Drug market, by application, 2015 - 2026 (USD Million)

  • Table Asia Pacific Diabetes Drug market, by country, 2015 - 2026 (USD Million)

  • Table Asia Pacific Diabetes Drug market, by type, 2015 - 2026 (USD Million)

  • Table Asia Pacific Diabetes Drug market, by product, 2015 - 2026 (USD Million)

  • Table Asia Pacific Diabetes Drug market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table China Diabetes Drug market, by type, 2015 - 2026 (USD Million)

  • Table China Diabetes Drug market, by product, 2015 - 2026 (USD Million)

  • Table China Diabetes Drug market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Japan Diabetes Drug market, by type, 2015 - 2026 (USD Million)

  • Table Japan Diabetes Drug market, by product, 2015 - 2026 (USD Million)

  • Table Japan Diabetes Drug market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table India Diabetes Drug market, by type, 2015 - 2026 (USD Million)

  • Table India Diabetes Drug market, by product, 2015 - 2026 (USD Million)

  • Table India Diabetes Drug market, by application, 2015 - 2026 (USD Million)

  • Table Latin America Diabetes Drug market, by country, 2015 - 2026 (USD Million)

  • Table Latin America Diabetes Drug market, by type, 2015 - 2026 (USD Million)

  • Table Latin America Diabetes Drug market, by product, 2015 - 2026 (USD Million)

  • Table Latin America Diabetes Drug market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Brazil Diabetes Drug market, by type, 2015 - 2026 (USD Million)

  • Table Brazil Diabetes Drug market, by product, 2015 - 2026 (USD Million)

  • Table Brazil Diabetes Drug market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Mexico Diabetes Drug market, by type, 2015 - 2026 (USD Million)

  • Table Mexico Diabetes Drug market, by product, 2015 - 2026 (USD Million)

  • Table Mexico Diabetes Drug market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Argentina Diabetes Drug market, by type, 2015 - 2026 (USD Million)

  • Table Argentina Diabetes Drug market, by product, 2015 - 2026 (USD Million)

  • Table Argentina Diabetes Drug market, by application, 2015 - 2026 (USD Million)

  • Table MEA Diabetes Drug market, by country, 2015 - 2026 (USD Million)

  • Table MEA Diabetes Drug market, by type, 2015 - 2026 (USD Million)

  • Table MEA Diabetes Drug market, by product, 2015 - 2026 (USD Million)

  • Table MEA Diabetes Drug market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table South Africa Diabetes Drug market, by type, 2015 - 2026 (USD Million)

  • Table South Africa Diabetes Drug market, by product, 2015 - 2026 (USD Million)

  • Table South Africa Diabetes Drug market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Nigeria Diabetes Drug market, by type, 2015 - 2026 (USD Million)

  • Table Nigeria Diabetes Drug market, by product, 2015 - 2026 (USD Million)

  • Table Nigeria Diabetes Drug market, by application, 2015 - 2026 (USD Million)

  • Table Recent Developments & Impact Analysis, by Key Market Participants

  • Table Recent Developments & Impact Analysis, by Key Market Participants

  • Table Company market position analysis

  • Table Company Profiles

  • Table Julphar. Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Novartis, Astellas Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Boehringer Ingelheim. Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Sanofi. Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Bristol Myers Squibb. Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Eli Lilly. Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Biocon. Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Pfizer. Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Exir. Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table AstraZeneca. Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Wockhardt. Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Abbott Laboratories. Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Merck. Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Mylan. Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table NovoNordisk. Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table SEDICO. Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Johnson & Johnson. Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table GlaxoSmithKline PLC. Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

Report Purchase

reports
$3850
$7700
BUY NOWClick MeBUY NOW
top